Purpose: Emerging cardiovascular biomarkers, such as speckle tracking echocardiography (STE) and aortic pulse wave velocity (aPWV), recently demonstrated subclinical left ventricular dysfunction and arterial stiffening in patients with chronic kidney disease (CKD) and no previous cardiovascular history. However, limited information exists on the prognostic impact of these biomarkers. We aimed to investigate whether STE and aPWV predict major adverse cardiac events (MACE) in this patient population. Methods and Results: In this cohort study we prospectively analysed 106 CKD patients with no overt cardiovascular disease (CVD) and normal left ventricular ejection fraction (LVEF). Cardiac deformation was measured using STE while aPWV was measured using arterial tonometry. The primary end-point was the composite of allcause mortality, acute coronary syndrome, stable angina requiring revascularization [either using percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG)], hospitalization for heart failure and stroke. Over a median follow up period of 49 months (interquartile range 11-63 months), 26 patients (24.5%) reached the primary endpoint. In a multivariable Cox hazards model, global longitudinal strain (GLS) (HR 1.12, 95% CI 1.02 -1.29, p = 0.041) and aPWV (HR 1.31, 95% CI 1.05-1.41, p = 0.021) were significant, independent predictors of MACE. Conclusion: GLS and aPWV independently predict MACE in CKD patients with no normal EF and no clinically overt CVD. Fig. 1 legend: . Kaplan -Meier time to primary endpoint curves stratified according to a GLS and aPWV of -17.7% and 10.2m/s respectively. Patients with GLS more then (less negative) -17.7% and aPWV more than 10.2m/s were more likely to reach a primary endpoint at a median follow up of 49 months69months.
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